Invesco Ltd. Grows Position in Merck & Co., Inc. $MRK

Invesco Ltd. raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,546,185 shares of the company’s stock after purchasing an additional 701,249 shares during the period. Invesco Ltd.’s holdings in Merck & Co., Inc. were worth $2,162,691,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $3,997,933,000. Wellington Management Group LLP raised its position in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after buying an additional 11,156,354 shares during the period. DLD Asset Management LP raised its position in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the period. Cardano Risk Management B.V. acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $1,012,530,000. Finally, Jennison Associates LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $585,192,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 1.2%

Shares of Merck & Co., Inc. stock opened at $114.04 on Friday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The stock has a market cap of $281.65 billion, a price-to-earnings ratio of 32.12, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a fifty day moving average price of $116.12 and a 200 day moving average price of $113.60.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company posted $2.22 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Analyst Upgrades and Downgrades

Several brokerages have commented on MRK. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.